+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By End Use (Private Healthcare Settings), By Region, And Segment Forecasts, 2025 - 2030- Product Image
Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By End Use (Private Healthcare Settings), By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By End Use (Private Healthcare Settings), By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • June 2025
  • Region: Global
  • Grand View Research
  • ID: 5457648
Description Jump to:

Shingles Vaccine Market Growth & Trends

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.7% from 2025 to 2030. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights

  • The Shingrix segment dominated the shingles vaccine market in 2024, accounting for the largest revenue share of 94.14%.
  • The private healthcare settings segment dominated the shingles vaccine market, accounting for the largest revenue share of 68.33% in 2024.
  • The recombinant vaccine segment accounted for the largest share of the shingles vaccine market in 2024, comprising a revenue share of 94.14%.
  • North America shingles vaccine market led the global market in 2024, holding the largest revenue share of 62.26%

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Shingles Vaccine Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. shingles vaccine Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Shingles Vaccine Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Shingles Vaccine Market: Product Movement Analysis, 2024 & 2030 (USD Million)
4.3. Shingrix
4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Zostavax
4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. SKYZoster
4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Shingles Vaccine Market: Vaccine Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Shingles Vaccine Market: Vaccine Type Movement Analysis, 2024 & 2030 (USD Million)
5.3. Recombinant Vaccine
5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Live Attenuated Vaccine
5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Shingles Vaccine Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Shingles Vaccine Market: Type Movement Analysis, 2024 & 2030 (USD Million)
6.3. Private Healthcare Settings
6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Government Healthcare Settings
6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Shingles Vaccine Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Argentina
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. GlaxoSmithKline plc.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Merck & Co., Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. CanSinoBIO
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Vaccitech
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Green Cross Corp
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Geneone Life Science
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. SK Bioscience
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global Shingles Vaccines Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 6 Global Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 7 Global Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 8 North America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 10 North America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 11 North America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 12 U.S Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 13 U.S Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 14 U.S Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 15 Canada Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 16 Canada Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 17 Canada Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 18 Mexico Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 19 Mexico Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 20 Mexico Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 21 Europe Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
Table 22 Europe Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 23 Europe Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 24 Europe Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 25 UK Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 26 UK Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 27 UK Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 28 Germany Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 29 Germany Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 30 Germany Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 31 France Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 32 France Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 33 France Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 34 Italy Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 35 Italy Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 36 Italy Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 37 Spain Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 38 Spain Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 39 Spain Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 40 Denmark Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 41 Denmark Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 42 Denmark Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 43 Sweden Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 44 Sweden Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 45 Sweden Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 46 Norway Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 47 Norway Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 48 Norway Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 52 Asia Pacific Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 53 Japan Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 54 Japan Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 55 Japan Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 56 China Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 57 China Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 58 China Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 59 India Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 60 India Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 61 India Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 62 South Korea Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 63 South Korea Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 64 South Korea Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 65 Australia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 66 Australia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 67 Australia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 68 Thailand Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 69 Thailand Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 70 Thailand Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 71 Latin America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
Table 72 Latin America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 73 Latin America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 74 Latin America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 75 Brazil Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 76 Brazil Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 77 Brazil Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 78 Argentina Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 79 Argentina Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 80 Argentina Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 81 Middle East and Africa Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
Table 82 Middle East and Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 83 Middle East and Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 84 Middle East & Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 85 South Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 86 South Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 87 South Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 91 UAE Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 92 UAE Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 93 UAE Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
Table 94 Kuwait Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
Table 95 Kuwait Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 96 Kuwait Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Shingles Vaccine market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot-1
Fig. 14 Segment snapshot-2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market trends & outlook
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 Shingles Vaccine market: Product outlook key takeaways
Fig. 20 Shingles Vaccine market: Product movement analysis
Fig. 21 Shingrix market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 22 Zostavax market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 23 SKYZoster market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 24 Shingles Vaccine market: Vaccine Type outlook key takeaways
Fig. 25 Shingles Vaccine market: Vaccine Type movement analysis
Fig. 26 Recombinant vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 27 Live attenuated vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 28 Shingles Vaccine market: End Use outlook key takeaways
Fig. 29 Shingles Vaccine market: End Use movement analysis
Fig. 30 Private healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 31 Government healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 32 Regional marketplace outlook, 2024 & 2030 (USD million)
Fig. 33 Regional marketplace: Key takeaways
Fig. 34 North America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 35 Key country dynamics
Fig. 36 U.S. shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 37 Key country dynamics
Fig. 38 Canada shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 39 Key country dynamics
Fig. 40 Mexico shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 41 Europe shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 42 Key country dynamics
Fig. 43 UK shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 44 Key country dynamics
Fig. 45 Germany shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 46 Key country dynamics
Fig. 47 France shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 48 Key country dynamics
Fig. 49 Spain shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 50 Key country dynamics
Fig. 51 Italy shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 52 Key country dynamics
Fig. 53 Denmark shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 54 Key country dynamics
Fig. 55 Sweden shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 56 Key country dynamics
Fig. 57 Norway shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 58 Asia Pacific shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 59 Key country dynamics
Fig. 60 Japan shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 61 Key country dynamics
Fig. 62 China shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 63 Key country dynamics
Fig. 64 India shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 65 Key country dynamics
Fig. 66 Australia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 67 Key country dynamics
Fig. 68 South Korea shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 69 Key country dynamics
Fig. 70 Thailand shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 71 Key country dynamics
Fig. 72 Latin America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 73 Key country dynamics
Fig. 74 Brazil shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 75 Key country dynamics
Fig. 76 Argentina shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 77 Key country dynamics
Fig. 78 Middle East & Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 79 Key country dynamics
Fig. 80 South Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 81 Key country dynamics
Fig. 82 Saudi Arabia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 83 Key country dynamics
Fig. 84 UAE shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 85 Key country dynamics
Fig. 86 Kuwait shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 87 Market participant categorization
Fig. 88 Shingles vaccine market position analysis, 2024
Fig. 89 Strategic framework

Companies Mentioned

  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • CanSinoBIO
  • Vaccitech
  • Green Cross Corp
  • Geneone Life Science
  • SK Bioscience

Table Information

Report AttributeDetails
No. of Pages100
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.78 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.26 Billion
Compound Annual Growth Rate15.7%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Shingles Vaccine Market by Vaccine Type, Age Group, End User, Distribution Channel, Dosage - Global Forecast to 2030 - Product Image

Shingles Vaccine Market by Vaccine Type, Age Group, End User, Distribution Channel, Dosage - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Shingles Vaccines - Global Strategic Business Report - Product Image

Shingles Vaccines - Global Strategic Business Report

  • Report
  • 269 Pages
  • Global
From
Shingrix (Zostavax) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Shingrix (Zostavax) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Zostavax Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Zostavax Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.